Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xoma diabetes drug fails to meet primary endpoint
Xoma 052, which is being jointly developed by Xoma and Servier, is a monoclonal antibody with the potential to improve the treatment of patients with a wide variety
Xoma 052, which is being jointly developed by Xoma and Servier, is a monoclonal antibody with the potential to improve the treatment of patients with a wide variety
The patent entitled: ‘Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors,’ protects NX002 and related compounds. Currently, NX002 is in preclinical development for the
Canbex said the award will further support the preclinical trials of the company’s VSN series of compounds. The company expects to initiate Phase I trial of VSN16R, company’s
Prolia, administered as a single subcutaneous injection of 60mg once every six months, specifically targets RANK Ligand, an essential regulator of osteoclasts (the cells that break down bone).
Xirrus said its Wi-Fi Arrays deliver a robust, high capacity network with unreserved wireless coverage, seamlessly achieving a solid Wi-Fi connection. EMA Information and Communications Technology head Hans-Georg
The company posted a net loss of $2.91m, compared to a net income of $0.32m for the same period in 2009. For the full year ended 31 December
The Phase III 48-week clinical trial evaluating the non-inferiority of Elvitegravir versus Raltegravir each administered with a background regimen in HIV-infected treatment-experienced adults with HIV RNA (viral load)
EZ-MAR is a computerized, web-based application, replaces a skilled nursing facility or institutionalized care provider’s paper records with an electronic means of maintaining medical treatment and medication administration
ARX8203 has showed positive and significant safety profile in GI toxicity studies compared with Diclofenac and Indomethacin, two very popular and currently marketed NSAIDs. AlphaRx has developed three
The drug has been approved as a treatment for endema associated with congestive heart failure, renal disease, or hepatic disease. Qualitest Pharma said the FDA’s approval for Toresmide